Johanna Patricia Adevoso Cañal

Johanna Patricia Adevoso Cañal

Auto-generated profile, based on publicly available information

Johanna Patricia Adevoso Cañal

University of the Philippines Manila

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMary Ann D. Lansang
Mary Ann D. Lansang
MAMarissa M. Alejandria
Marissa M. Alejandria
ILIrwin Law
Irwin Law
NJNoel R. Juban
Noel R. Juban
MAMaria Lourdes E. Amarillo
Maria Lourdes E. Amarillo
PGPhilippine NTPS 2016 Group
Philippine NTPS 2016 Group
Setting: The 3rd national tuberculosis (TB) survey in the Philippines in 2007 reported a significant decline in the prevalence of TB. Since then, more significant investments for TB control have been made, yet TB burden estimates from routine surveillance data remain relatively stable. Objective: To estimate the prevalence of bacteriologically confirmed pulmonary TB in the Philippines amongst individuals aged ≥15 years in 2016. Design: In March–December 2016, we conducted a population-based survey with stratified, multi-stage cluster sampling of residents in 106 clusters aged ≥15 years. Survey participants were screened for TB by symptom-based interview and digital chest X-ray. Those with cough ≥2 weeks and/or haemoptysis and/or chest X-ray suggestive of TB were requested to submit 2 sputum specimens for Xpert MTB/RIF, direct sputum smear microscopy using LED fluorescent microscopy, and mycobacterial solid culture (Ogawa method). Bacteriologically confirmed pulmonary TB was defined as MTB culture positive and/or Xpert positive. Results: There were 46,689 individuals interviewed, and 41,444 (88.8%) consented to a chest X-ray. There were 18,597 (39.8%) eligible for sputum examination and 16,242 (87.3%) submitted at least one specimen. Out of 16,058 sputum-eligible participants, 183 (1.1%) were smear-positive. There were 466 bacteriologically confirmed TB cases: 238 (51.1%) Xpert positive, 69 (14.8%) culture positive, and 159 (34.1%) positive by both Xpert and culture. The estimated TB prevalence per 100,000 population aged ≥15 years was 434 (95% CI: 350−518) for smear-positive TB, and 1,159 (95% CI: 1,016−1,301) for bacteriologically confirmed TB. Conclusion: This nationally representative survey found that the TB burden in the Philippines in 2016 was higher than estimated from routine TB surveillance data. There was no evidence of a decline in smear and culture positive TB from the 2007 survey despite significant investments in TB control. New strategies for case-finding and patient-centered care must be intensified and expanded.

4 November 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MEMichelle Ann B. Eala
Michelle Ann B. Eala
EMEthan Angelo S. Maslog
Ethan Angelo S. Maslog
EDEdward Christopher Dee
Edward Christopher Dee
FTFrederic Ivan Ting
Frederic Ivan Ting
JTJean Anne B. Toral
Jean Anne B. Toral
JCJohanna Patricia A. Cañal
Johanna Patricia A. Cañal
PURPOSE: In the Philippines, a lower middle-income country in Southeast Asia, 6 of 10 Filipinos die without seeing a doctor. To ensure universal access to cancer care, providers must be equitably distributed. Therefore, we evaluated the distribution of oncologists across all 17 regions in the Philippines. METHODS: We gathered data from the official websites of national medical societies on their members' regional area of practice: Philippine Society of Medical Oncology, Philippine Radiation Oncology Society, Surgical Oncology Society of the Philippines, Society of Gynecologic Oncologists of the Philippines, and Philippine Society of Hospice and Palliative Medicine. We compared this with the regional census to determine the number of board-certified oncologists per 100,000 Filipinos. RESULTS: For a population of almost 110 million, the Philippines has a total of 348 medical oncologists, 164 surgical oncologists, 99 radiation oncologists, 142 gynecologic oncologists, and 35 hospice and palliative medicine (HPM) specialists. This translates to 0.32 medical oncologists, 0.15 surgical oncologists, 0.09 radiation oncologists, 0.13 gynecologic oncologists, and 0.03 HPM specialists for every 100,000 Filipinos. The number of oncologists is highest in the National Capital Region in Luzon and lowest in the Bangsamoro Autonomous Region in Muslim Mindanao. All regions have at least one medical and gynecologic oncologist. Two regions (12%) have no surgical oncologists, five regions (29%) have no radiation oncologists, and eight regions (47%) have no HPM specialists. CONCLUSION: Efforts are needed to increase the number of oncologists and improve equity in their distribution to ensure universal access to cancer care in the Philippines.

11 May 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ECElla Mae Cruz-Lim
Ella Mae Cruz-Lim
RCReno Eufemon Cereno
Reno Eufemon Cereno
JCJohanna Patricia Cañal
Johanna Patricia Cañal
GVGaudencio Vega
Gaudencio Vega
EIElrick Inocencio
Elrick Inocencio
BMBenjamin Mou
Benjamin Mou

6 February 2022 in IJID Regions
Verified
Journal Article
Open access
AMAnna Flor G. Malundo
Anna Flor G. Malundo
CACybele Lara R. Abad
Cybele Lara R. Abad
MSMaria Sonia S. Salamat
Maria Sonia S. Salamat
JSJoanne Carmela M. Sandejas
Joanne Carmela M. Sandejas
JPJose Eladio G. Planta
Jose Eladio G. Planta
MAMarissa M. Alejandria
Marissa M. Alejandria
To describe the clinical profile and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) across the spectrum of disease severity. This retrospective study included adult patients with confirmed COVID-19 infection admitted to a referral hospital. Descriptive statistics, tests for trend, Kaplan–Meier curve and log-rank test were used to compare characteristics and outcomes across disease severity categories. Of 1500 patients with COVID-19, 14.8% were asymptomatic, 13.5% had mild disease, 36.6% had moderate disease, 12.3% had severe disease and 22.7% had critical disease. Asymptomatic patients were admitted for a concurrent condition or for isolation. Patients aged >60 years, male gender and with co-morbidities had more severe disease. Fever, cough, shortness of breath, malaise, gastrointestinal symptoms and decreased sensorium were more common in patients with severe disease. Bilateral pulmonary infiltrates were common (51.1%), with sicker patients having more abnormal findings. The overall mortality rate was 15.1%. Adopting a symptom-based strategy reduced the length of hospitalization from a median of 13 [interquartile range (IQR) 7–21] days to 9 (IQR 5–14) days. The clinical profile and outcomes for this cohort of patients with COVID-19 was consistent with published reports. Asymptomatic infection was common, and universal testing may be a valuable strategy in the correct context, given the implications for infection control. A symptom-based strategy was found to reduce the length of hospitalization considerably.

14 July 2022 in IJID Regions
Verified
Journal Article
Open access
AMAnna Flor G. Malundo
Anna Flor G. Malundo
CACybele Lara R. Abad
Cybele Lara R. Abad
MSMaria Sonia S. Salamat
Maria Sonia S. Salamat
JSJoanne Carmela M. Sandejas
Joanne Carmela M. Sandejas
JPJonnel B. Poblete
Jonnel B. Poblete
MAMarissa M. Alejandria
Marissa M. Alejandria
The aim of this study was to determine the predictors of mortality and describe laboratory trends among adults with confirmed COVID-19. The medical records of adult patients admitted to a referral hospital with COVID-19 were retrospectively reviewed. Demographic and clinical characteristics, and laboratory parameters, were compared between survivors and non-survivors. Predictors of mortality were determined by multivariate analysis. Mean laboratory values were plotted across illness duration. Of 1215 patients, 203 (16.7%) had mild, 488 (40.2%) moderate, 183 (15.1%) severe, and 341 (28.1%) critical COVID-19 on admission. In-hospital mortality was 18.2% (0% mild, 6.1% moderate, 15.8% severe, 47.5% critical). Predictors of mortality were age ≥ 60 years, COPD, qSOFA score ≥ 2, WBC > 10 × 109/L, absolute lymphocyte count < 1000, neutrophil ≥ 70%, PaO2/FiO2 ratio ≤ 200, eGFR < 90 mL/min/1.73 m2, LDH > 600 U/L, and CRP > 12 mg/L. Non-survivors exhibited an increase in LDH and decreases in PaO2/FiO2 ratio and eGFR during the 2nd–3rd week of illness. The overall mortality rate was high. Predictors of mortality were similar to those of other reports globally. Marked inflammation and worsening pulmonary and renal function were evident among non-survivors by the 2nd–3rd week of illness.

1 December 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
MEMichelle Ann B Eala
Michelle Ann B Eala
KMKatherine Donatela Manlongat
Katherine Donatela Manlongat
EDEdward Christopher Dee
Edward Christopher Dee
RBRonnie E Baticulon
Ronnie E Baticulon
JCJohanna Patricia A Canal
Johanna Patricia A Canal